Publications Citing Rapid Novor’s Technology.

1. Arboleda-Velasquez, J.F., Lopera, F., O’Hare, M., et al. (2019) Resistance to autosomal dominant Alzheimer’s disease APOE3 Christchurch homozygote: a case report. Nat Med 25 1680-1683. https://doi.org/10.1038/s41591-019-0611-3

2. Kierkels, G.J.J. (2019). TCR engineered T cell therapy from concepts to clinic. Utretch University Repository. https://dspace.library.uu.nl/handle/1874/379914

3. Bratslavsky, G., Tsimafeyeu I (2019). Identification of first-in-class, naturally occurring LAG3 checkpoint inhibitor. Annals of Oncology 30(5): 499P (https://www.annalsofoncology.org/article/S0923-7534(19)58721-X/pdf)

4. Nešić, D. et al. (2020) Cryo-Electron Microscopy Structure of the αIIbβ3-Abciximab Complex. Arteriosclerosis, Thrombosis, and Vascular Biology 40: 624-637 https://www.ahajournals.org/doi/full/10.1161/ATVBAHA.119.313671

5. Towards antigen-specific Tregs for type 1 diabetes: Construction and functional assessment of pancreatic endocrine marker, HPi2-based chimeric antigen receptor. Cellular Immunol 358 (2020): 104224. https://doi.org/10.1016/j.cellimm.2020.104224

6. Dai et al. (2021) Polymeric assembly of endogenous Tuberous Sclerosis Protein Complex. Biochemistry 60(23):1808-1821 doi: 10.1021/acs.biochem.1c00269

7. Dang et al. (2021) Broadly neutralizing antibody cocktails targeting Nipah virus and Hendra virus fusion glycoproteins. Nat Structural & Mol Bio 28: 426-434. https://www.nature.com/articles/s41594-021-00584-8#Sec27

8. Kierkels, G. J. J., van Diest, E., Hernandez-Lopez, P., et al. (2021). Characterization and modulation of anti-αβTCR antibodies and their respective binding sites at the βTCR chain to enrich engineered T cells. Mol Ther Methods & Clin Dev 22: 388-400 https://doi.org/10.1016/j.omtm.2021.06.011

9. DeLuca et al. (2021) Generation and diversification of recombinant monoclonal antibodies for studying mitosis. eLife 10: e72093 https://doi.org/10.7554/eLife.72093

10. Wang et al. (2021) First Immunoassay for Measuring Isoaspartate in Human Serum Albumin. Molecules 26(21): 6709 https://doi.org/10.3390/molecules26216709

Patents Citing Rapid Novor’s Technology.

1. CARNEGIE INSTITUTION OF WASHINGTON. (2017). Regeneration of aged satellite cells. United States Patent Application US20170369578A1 https://patents.google.com/patent/US20170369578?oq=%22rapid+novor%22

2. Capienda Biotech. WIPO Patent Application WO/2019/195179 (2019) COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISEASES. https://www.sumobrain.com/patents/wipo/Compositions-methods-treating-inflammatory-diseases/WO2019195179A1.html

3. Souvie Biodelivery, LLC. (2020) US Patent Application US 20200362052 COMPOSITIONS AND METHODS FOR TREATING TOLL-LIKE RECEPTOR-DRIVEN INFLAMMATORY DISEASES.

4. Biond Bioligics LTD. (2020). SMALL SHEDDING BLOCKING AGENTS. https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020183473

5. Biond Bioligics LTD. (2021). METHODS AND COMPOSITIONS FOR DECREASING SOLUBLE IMMUNE RECEPTOR CD28. https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2019175885

6. Janssen Biotech, Inc. (2021) United States Patent Application US20210284731 A1. METHODS AND MATERIALS FOR MODULATING AN IMMUNE RESPONSE.

7. Janssen Biotech, Inc. (2021) United States Patent Application 20210032338 MATERIALS AND METHODS FOR MODULATING T CELL MEDIATED IMMUNITY. https://www.freepatentsonline.com/y2021/0032338.html

Posters and Publications from Rapid Novor.

1. Taylor et al. (2016) In-Depth Characterization of Monoclonal Antibodies with a Single Experiment and Fully Automated Data Analysis. ASMS: MP018 https://www.rapidnovor.com/resources/asms-2016-poster/

2. McDonald, Z., Liu Q., Xie, M., Ma, B., Taylor, P., & Stajduhar, A. (2018). Studying the Prevalence of Secondary Light Chains in Research Purpose Monoclonal Antibodies with MS-Based De Novo Protein Sequencing. ASMS 2018 San Diego, MP 063 https://www.rapidnovor.com/research/prevalence-of-secondary-light-chains/

3. Le Bihan, T. et al. (2019). Increased De Novo Protein Sequencing Coverage with Optimal Protease Cocktail. ASMS 2019 Atlanta, TP 020 https://www.rapidnovor.com/learning-centre/antibody-mass-spectrometry/study-increased-de-novo-protein-sequencing-coverage-with-optimal-protease-cocktail/

4. McDonald et al. 2019. Targeted Mass Spectrometry-Based Serum M-Protein Monitoring for Early Relapse Detection. Blood 134 (Supp. 1): 4347 https://ashpublications.org/blood/article/134/Supplement_1/4347/424584/Targeted-Mass-Spectrometry-Based-Serum-M-Protein

5. Le Bihan, T. et al. (2020). A labeling strategy to improve peptide fragmentation and to distinguish isobaric amino acids by EThcD. ASMS 2020, TP 033 https://www.asms.org/docs/default-source/2020-reboot-files/posters_all-days-w-overview_may-9.pdf?sfvrsn=fc3371c3_2

6. Guan et al. (2020) Data Dependent–Independent Acquisition (DDIA) Proteomics. J Proteome Res. 19(8): 3230-3237 https://pubs.acs.org/doi/abs/10.1021/acs.jproteome.0c00186

7. Liu, Q., Reinhardt, N., and Ma, B. (2020) Rapid Total Search: Peptide Identification in 200 Million Proteins with Unrestricted Modifications and Nonspecific Digestion. ASMS 2020. ThP 289

8. Liyasova et al. (2021) A Personalized Mass Spectrometry–Based Assay to Monitor M-Protein in Patients with Multiple Myeloma (EasyM). Clin Cancer Res 28(18): 5028 – 5037 DOI: 10.1158/1078-0432.CCR-21-0649

9. McDonald et al. (2021) Mass Spectrometry Provides a Highly Sensitive Noninvasive Means of Sequencing and Tracking M-Protein in the Blood of Multiple Myeloma Patients. J. Proteome Res 20(8): 4176-4185 https://doi.org/10.1021/acs.jproteome.0c01022

10. Perez-Witzke, D., and Nunez de Villavicencio Diaz, T., et al. 2021. Sequencing and expression of monoclonal antibodies from a polyclonal goat antibody sample. PEGS Europe. https://www.rapidnovor.com/sequencing-recombinant-goat-polyclonal-antibodies/

Recent Publications Citing Novor Software.

1. Nair et al. (2018) Identification, purification, biochemical and mass spectrometric characterization of novel phycobiliproteins from a marine red alga, Centroceras clavulatum. Intl. J. Biological Macromolecules 114: 679-691 https://www.sciencedirect.com/science/article/abs/pii/S0141813017348018

2. Vyatkina, K.V. (2018) De novo Sequencing of Proteins and Peptides: Algorithms, Applications, Perspectives. Biomed. Chem: Res & Met 1(1) http://195.178.207.145/index.php/bmcrm/article/view/5

3. Vanuopadatha, M. et al. (2020) Delineating the venom toxin arsenal of Malabar pit viper (Trimeresurus malabaricus) from the Western Ghats of India and evaluating its immunological cross-reactivity and in vitro cytotoxicity. Intl. J. Biological Molecules 148: 1029-1045 https://www.sciencedirect.com/science/article/abs/pii/S0141813019400706

4. Nogueira, F. C. S. et al. (2021) Ancient enamel peptides recovered from the South American Pleistocene species Notiomastodon platensis and Myocastor cf. coypus. J. Proteomics. 240: 104187 https://www.sciencedirect.com/science/article/abs/pii/S1874391921000865#ks0005

On the News.

1. Malki, J. (2019) “It will take longer than you expect — don’t give up.” Charles Cotropia of BioClonetics Immunotherapeutics. https://medium.com/strtupboost/it-will-take-longer-than-you-expect-dont-give-up-628540171cb5

2. Rosales Gerpe, M. and Barber, J. (2019) How Mass Spectrometry Can Help Limit Reproducibility Problems. Scientific American. https://blogs.scientificamerican.com/observations/how-mass-spectrometry-can-help-limit-reproducibility-problems/

3. Rapid Novor. (2021) Deep dive into immunity: decode with proteogenomics Biopharma Dealmakers. https://www.nature.com/articles/d43747-021-00006-0

4. News Medical (2020) Polyclonal Antibody Sequencing for the Next Generation Antibody Discovery. https://www.news-medical.net/whitepaper/20201202/Polyclonal-Antibody-Sequencing-for-the-Next-Generation-Antibody-Discovery

Talk to Our Scientists.

We Have Sequenced 5000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.

Talk to Our Scientists.

We Have Sequenced 5000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics

Talk to our scientists. We have sequenced over 5000 antibodies and we are eager to help you.